About Tina Dackemark Lawesson
This author has yet to write their bio.
Meanwhile lets just say that we are proud Tina Dackemark Lawesson contributed a whooping 55 entries.
On December 4-5, SenzaGen was attending BioFIT in Lille, France. BioFIT is a business development meeting with focus on early stage innovations including pre-clinical stage assets. We met with CROs and life science companies from all over Europe in search of screening tools at pre-clinical stage. Read more about Biofit here: https://www.biofit-event.com
SenzaGen is attending the Society of Toxicology (STC) of Canada’s 50th Annual Symposium, on December 10-12 in Toronto, Canada. Joshua Schmidt, Business Development Director Americas at SenzaGen, will participate at the symposium and present the poster: GARD – Assessing Skin and Respiratory Sensitizers in vitro using a genomics-based platform. STC is a non-profit association whose objectives […]
Dr Andy Forreryd, scientist at SenzaGen, is one of three speakers at the Human Safety Seminar organised by Eurofins BioPharma Product Testing Munich where he will be presenting the GARD® platform for skin and respiratory sensitization. The seminar will be hosted on November 29 at the new laboratory and office building of Eurofins Munich, Robert-Koch-Straße 3a in Planegg near Munich, Germany. […]
SenzaGen is attending the Biocompatibility Summit in Barcelona this week, on November 27-29. The summit will address updates and changes to the ISO 10993 standards and Biocompatibility for devices with a focus on Risk Mitigation, Chemical Characterisation and Practical Implementation. Come meet our colleagues and specialists Rose Marie Jenvert, Medical Device Project Manager and Joshua Schmidt, […]
SenzaGen is attending the SFT conference (Société Française de Toxicologie) in Lille, France, on November 27-28. The conference is the French Society of Toxicology’s annual meeting and SenzaGen is present with a poster: GARD® – Genomic Allergen Rapid Detection, In vitro Safety Assessment of Skin and Respiratory Sensitizers using a Genomics Based Platform. Our French […]
On October 10, SenzaGen participated in the Vator Securities Unicorn Summit, a capital market day organized to bring together some of the most innovative and fast-growing Swedish life science companies with investors. Anki Malmborg Hager presented Senzagen’s developments and accelerated efforts towards further strengthening the commercial organization and the global presence of GARD®, a group of tests for animal-free safety testing. […]
On October 15, SenzaGen’s CEO Anki Malmborg Hager was interviewed by Swedish financial media EFN about SenzaGen’s cruelty-free test platform GARD®, our business model and new sales targets. The result was a short and to-the-point interview about our core business and our future. You will find the filmed interview (in Swedish) here: https://www.efn.se/bors-finans/senzagen-ersatter-djurforsok-kemikalietester/
David W Roberts, Liverpool John Moores University, Liverpool Introduction – Non-Animal Prediction: the 21st Century Consensus Because of the biological complexity of the skin sensitisation process no single in chemico or in vitro assay will be an appropriate replacement for an animal-based assay such as LLNA or GPMT… …to ensure a mechanistic basis and cover the […]
SenzaGen will participate in the Vator Securities Unicorn Summit, which takes place today, October 10, at Medicon Village in Lund. Anki Malmborg Hager will present Senzagen´s developments and accelerated efforts towards further strengthening the commercial organization and the global presence of SenzaGen’s platform GARD®, a group of tests for animal-free safety testing. Unicorn Summit is a capital market day organized by Vator Securities to bring together some […]